MECP2 and breast carcinoma: Studies have also shown that MeCP2 can inhibit the transcription of RPL11 and RPL5 by binding to the promoter regions of RPL11 and RPL5, thereby promoting breast cancer cell proliferation and inhibiting apoptosis [8].